Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market” Quick Read – Jim Cramer predicts a biotech takeover flood, with Lilly posting $19.8B Q1 revenue and Gilead closing a $7.8B acquisition already leading the…
arge. – Vertex and Regeneron hold the confirmed-data franchises Cramer says command premium acquisition prices, with Dupixent hitting $4.88B in global sales. – A near-blocked Amgen deal under the prior administration froze biotech M&A for years, and the FDA leadership change has only now thawed it. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn’t make the cut. Grab the names FREE today
On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking. “There is a move in biotech that we have not talked about at all that is really extraordinary, and particularly since the change at the head of the FDA,” Cramer said. “If you look at that chart, this is the group that’s the hottest group in the market.” Cramer argued that takeover activity, which slowed under the previous administration after an Amgen acquisition nearly faced regulatory opposition, is poised to accelerate. Cramer noted that “we have now waited for so many companies because there have been so few takeovers under the previous administration because of an Amgen deal that was almost blocked,” and predicted that “these deals are going to be flooding the market according to my sources. And you want to be long biotech.
I have not said that in ages.” Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn’t make the cut. Grab the names FREE today. Why Eli Lilly Could Lead the Next Biotech Buying Spree Eli Lilly (NYSE:LLY) is one of the primary…